CD109 and glioblastoma: CD109+CECs were 26±20/mL in healthy subject (n = 50), 62±43/mL in metastatic breast cancer patients (n = 66, p<0.0001) and 101±84/mL in glioblastoma patients (n = 134, p<0.0001) before treatment.